Semaglutide official document review · version 1
This page preserves this version's findings, scope and source pins. Open the current profile →
Inside the official reviews
Reviewed 2026-09-19 · Preserved version 1
The initial Ozempic review concerns type 2 diabetes
EMA’s December 2017 assessment reports improvements in HbA1c and weight in controlled trials and a separate cardiovascular trial in people at high cardiovascular risk. It does not summarize later obesity, kidney or other indication-specific programs. EMA PDF pp. 154, 155 ↗
More findings, study links and document coverage
Cardiovascular outcomes were not uniformly improved
The review described benefit on some cardiovascular outcomes but neutral findings for cardiovascular death and all-cause death. It also cautioned against extrapolating the two-year high-risk trial to lower-risk populations. EMA PDF pp. 154, 155 ↗
Retinopathy was an observed safety signal
Serious retinopathy complications were more frequent with semaglutide in the reviewed trial, especially among participants with pre-existing retinopathy receiving insulin. EMA treated the mechanism as uncertain rather than proving a single explanation. EMA PDF pp. 147, 149, 155 ↗
Harms and duration matter alongside average benefit
Gastrointestinal adverse effects were frequent and clinically relevant. EMA also noted that two years is relatively short for chronic diabetes treatment, supporting longer follow-up rather than assuming that trial results settle every long-term risk. EMA PDF pp. 154, 155 ↗
Read the separate U.S. label account → Label version and indication scope are preserved there; these agency reviews describe their own dated evidence.
Document coverage
Selected sections read in 1 of 1 inventoried documents; 0 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.
One selected official document from the retained EMA document inventory or an independently retrieved FDA application package. Other formulations, later variations, national records and the wider source inventory remain outside this reading. EMA inventory source ↗
Inspect documents, application identities and source pins
Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.
Ozempic : EPAR - Public assessment report ↗
Selected sections reviewed · ema-14075 · Document/feed date: 2018-02-21
Application identity and document date were checked in the PDF, independently of the URL year or candidate feed association.
Verified: Ozempic · EMEA/H/C/004174 · Document dated 2017-12-14. Identity checked on PDF pp. 1.
Selected identity, clinical-summary and benefit-risk sections only; this is not a full-document or all-indication appraisal.
Retrieved 2026-09-19. Read PDF pages: 1, 147, 149, 154, 155 of 156. SHA-256:
71a57c0097238e05c51a99f58ace2036ea8d91ff70356300bc41573892a60a84.Feed-listed application (not a verified association): EMEA/H/C/004174.
Remaining work
- Review Wegovy obesity, subsequent cardiovascular and kidney assessments as distinct indication-specific programs.
- Reconcile later retinopathy evidence and formulation-specific safety updates with the original Ozempic assessment.